Ovarian cancer has been called the “silent killer,” because it often goes undetected until reaching an advanced stage. For more than 3 decades, oncologists have been searching for new ways to enhance the effectiveness of current treatments.
Kaiser Permanente patients have been participating in an international clinical trial to evaluate a promising new treatment called veliparib, one of a new class of PARP inhibitors drugs that prevent cancer cells from repairing damage to their DNA caused by mutations or chemotherapy.
Dr. Michael Bookman, medical director of gynecologic oncology therapeutics for Kaiser Permanente Northern California, explains; Janet Byron hosts.
